Regeneron’s Coronavirus Treatment Becomes First Antibody Cocktail to Earn Emergency Use Authorization from FDA
There’s a new coronavirus treatment option that will go a long way to prevent hospitals from getting swarmed with severe patients this winter. On Saturday night, Regeneron‘s (NASDAQ: REGN) COVID-19 treatment candidate, REGEN-COV2, earned emergency use authorization (EUA) from the FDA to treat recently diagnosed patients at high risk of becoming severely affected.
On Nov. 9, the FDA authorized bamlanivimab, an antibody treatment from Eli Lilly (NYSE: LLY) for the same group of patients. Lilly’s also working on a cocktail of its own that combines bamlanivimab and LY-CoV016. Both seek out and stick to spike proteins on the surface of SARS-CoV-2, the virus responsible for COVID-19.
Image source: Getty Images.